CLR II C 7.3 Level of disclosure required for antibodies

In T 431/96 the skilled person seeking to reproduce the invention would have had to produce monoclonal antibodies by routine methods and test them singly in an assay. Although this might possibly involve some tedious and time-consuming work, it was nothing out of the ordinary since the techniques for the production and selection of hybridomas were common routine techniques at the priority date of the patent in suit.

Pages

Subscribe to XEPC: EPC and PCT resource RSS